Contrasting effects on ganciclovir susceptibility and replicative capacity of two mutations at codon 466 of the human cytomegalovirus UL97 gene

Journal of Clinical Virology

Volumn 49, Issue 4, 2010, Pages 296-298

  Martin, Mélanie ^a   Goyette, Nathalie ^a   Boivin, Guy ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Ganciclovir; Human cytomegalovirus; Replication; Resistance; UL97 gene

Indexed keywords

GANCICLOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; CODON; CONTROLLED STUDY; DRUG EFFECT; DRUG SENSITIVITY; GENE MUTATION; GRAFT RECIPIENT; HUMAN; HUMAN CYTOMEGALOVIRUS; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; VIRUS GENE; VIRUS RECOMBINANT; VIRUS REPLICATION; WILD TYPE;

ANTIVIRAL AGENTS; CODON; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; GANCICLOVIR; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION, MISSENSE; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PLAQUE ASSAY; VIRUS REPLICATION;

EID: 78149499784     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2010.08.008     Document Type: Article

References (34)

1. Chou S., Marousek G., Guentzel S., Follansbee S.E., Poscher M.E., Lalezari J.P., et al. Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. J Infect Dis 1997, 176:786-789.
2. Erice A., Gil-Roda C., Perez J.L., Balfour H.H., Sannerud K.J., Hanson M.N., et al. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J Infect Dis 1997, 175:1087-1092.
3. Limaye A.P., Corey L., Koelle D.M., Davis C.L., Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000, 356:645-649.
4. Limaye A.P., Raghu G., Koelle D.M., Ferrenberg J., Huang M.L., Boeckh M. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis 2002, 185:20-27.
5. Smith I.L., Cherrington J.M., Jiles R.E., Fuller M.D., Freeman W.R., Spector S.A. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J Infect Dis 1997, 176:69-77.
6. Boivin G., Goyette N., Gilbert C., Covington E. Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis. J Med Virol 2005, 77:425-429.
7. Gilbert C., Boivin G. Human cytomegalovirus resistance to antiviral drugs. Antimicrob Agents Chemother 2005, 49:873-883.
8. Chou S., Lurain N.S., Weinberg A., Cai G.Y., Sharma P.L., Crumpacker C.S. Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. Antimicrob Agents Chemother 1999, 43:1500-1502.
9. Fillet A.M., Auray L., Alain S., Gourlain K., Imbert B.M., Najioullah F., et al. Natural polymorphism of cytomegalovirus DNA polymerase lies in two nonconserved regions located between domains delta-C and II and between domains III and I. Antimicrob Agents Chemother 2004, 48:1865-1868.
10. Martin M., Gilbert C., Covington E., Boivin G. Characterization of human cytomegalovirus (HCMV) UL97 mutations found in a valganciclovir/oral ganciclovir prophylactic trial by use of a bacterial artificial chromosome containing the HCMV genome. J Infect Dis 2006, 194:579-583.
11. Boivin G., Gilbert C., Gaudreau A., Greenfield I., Sudlow R., Roberts N.A. Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis. J Infect Dis 2001, 184:1598-1602.
12. Lurain N.S., Weinberg A., Crumpacker C.S., Chou S. Sequencing of cytomegalovirus UL97 gene for genotypic antiviral resistance testing. Antimicrob Agents Chemother 2001, 45:2775-2780.
13. Chou S., Van Wechel L.C., Lichy H.M., Marousek G.I. Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene. Antimicrob Agents Chemother 2005, 49:2710-2715.
14. Cihlar T., Fuller M., Cherrington J. Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. J Virol 1998, 72:5927-5936.
15. Scott G.M., Weinberg A., Rawlinson W.D., Chou S. Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. Antimicrob Agents Chemother 2007, 51:89-94.
16. Chou S. Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. Antimicrob Agents Chemother 2010, 54:2371-2378.
17. Chou S., Marousek G., Li S., Weinberg A. Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. J Clin Virol 2008, 43:107-109.
18. Martin M., Goyette N., Ives J., Boivin G. Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis. J Clin Virol 2010, 47:321-324.
19. Borst E.M., Hahn G., Koszinowski U.H., Messerle M. Cloning of the human cytomegalovirus (HCMV) genome as an infectious bacterial artificial chromosome in Escherichia coli: a new approach for construction of HCMV mutants. J Virol 1999, 73:8320-8329.
20. Landry M.L., Stanat S., Biron K., Brambilla D., Britt W., Jokela J., et al. A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates. Antimicrob Agents Chemother 2000, 44:688-692.
21. Chou S., Marousek G.I. Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant. J Virol 2008, 82:246-253.
22. Chou S., Meichsner C.L. A nine-codon deletion mutation in the cytomegalovirus UL97 phosphotransferase gene confers resistance to ganciclovir. Antimicrob Agents Chemother 2000, 44:183-185.
23. Chou S., Waldemer R.H., Senters A.E., Michels K.S., Kemble G.W., Miner R.C., et al. Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. J Infect Dis 2002, 185:162-169.
24. Emery V.C., Cope A.V., Bowen E.F., Gor D., Griffiths P.D. The dynamics of human cytomegalovirus replication in vivo. J Exp Med 1999, 190:177-182.
25. Gill R.B., Frederick S.L., Hartline C.B., Chou S., Prichard M.N. Conserved retinoblastoma protein-binding motif in human cytomegalovirus UL97 kinase minimally impacts viral replication but affects susceptibility to maribavir. Virol J 2009, 6:9.
26. Prichard M.N., Gao N., Jairath S., Mulamba G., Krosky P., Coen D.M., et al. A recombinant human cytomegalovirus with a large deletion in UL97 has a severe replication deficiency. J Virol 1999, 73:5663-5670.
27. Chou S., Wechel L.C., Marousek G.I. Cytomegalovirus UL97 kinase mutations that confer maribavir resistance. J Infect Dis 2007, 196:91-94.
28. Hanks S.K., Quinn A.M., Hunter T. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 1988, 241:42-52.
29. Baldanti F., Underwood M.R., Stanat S.C., Biron K.K., Chou S., Sarasini A., et al. Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. J Virol 1996, 70:1390-1395.
30. Chou S., Lurain N.S., Thompson K.D., Miner R.C., Drew W.L. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J Infect Dis 2003, 188:32-39.
31. Chou S., Marousek G.I., Van Wechel L.C., Li S., Weinberg A. Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. Antimicrob Agents Chemother 2007, 51:4160-4162.
32. Cihlar T., Fuller M.D., Mulato A.S., Cherrington J.M. A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture. Virology 1998, 248:382-393.
33. Boivin G., Goyette N., Gilbert C., Roberts N., Macey K., Paya C., et al. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J Infect Dis 2004, 189:1615-1618.
34. Boivin G., Goyette N., Rollag H., Jardine A.G., Pescovitz M.D., Asberg A., et al. Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. Antivir Ther 2009, 14:697-704.